Nimodipine treatment of selected good-risk patients with subarachnoid hemorrhage: no significant difference between present and historical results.
Eighty-four patients were treated early with nimodipine intravenously, and thereafter orally, up to 21 days after aneurysmal subarachnoid hemorrhage. Thirty-nine patients in the nimodipine-treated group were carefully selected to be compared with similar patients from a historical control group (114 patients) conventionally treated. The causes of poor results were clinically identified as follows: delayed ischemic deterioration (DID), rebleeding, complications of surgery, or not defined. There was no significant difference in the distribution of DID or outcome at follow-up examination (at least 6 months later) between the nimodipine-treated group and the control group.
Pellettieri
L
L
Department of Neurosurgery, University Hospital, Uppsala, Sweden.
Bolander
H
H
Carlsson
H
H
Sjölander
U
U
D000293:Adolescent; D000328:Adult; D002545:Brain Ischemia / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications; D007223:Infant; D007231:Infant, Newborn; D002532:Intracranial Aneurysm / Q000150:complications / Q000601:surgery; D008026:Ligation; D008875:Middle Aged; D009553:Nimodipine / Q000627:therapeutic use*; D012307:Risk Factors; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D013997:Time Factors
D009553:Nimodipine